SCHEMBL5049699

SCHEMBL5049699

CC1(C)CCC(C)(C)c2c(OCc3ccc(F)cc3)cc(C(O)C=Cc3ccc(C(=O)O)c(O)c3)cc21

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RARA P10276 2/20 0.43
RARB P10826 2/20 0.43
RARG P13631 1/20 0.43
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
AKR1C3 P42330 5/20 0.37
RXRA P19793 2/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
APP P05067 2/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
PTPN7 P35236 1/20 0.33
PTPN12 Q05209 1/20 0.33
PTPN22 Q9Y2R2 1/20 0.33
HPD P32754 1/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049694 1.00 RARA (0.43) RARARARBRARGMAOAMAOB
SCHEMBL5049692 1.00 RARA (0.43) RARARARBRARGMAOAMAOB
SCHEMBL5050673 0.93 RARA (0.44) RARARARBRARGAKR1C3RXRA
SCHEMBL5050679 0.93 RARA (0.44) RARARARBRARGAKR1C3RXRA
SCHEMBL5050676 0.93 RARA (0.44) RARARARBRARGAKR1C3RXRA
SCHEMBL5047250 0.91 RARA (0.42) RARARARBRARGMAOAMAOB
SCHEMBL5047259 0.91 RARA (0.42) RARARARBRARGMAOAMAOB
SCHEMBL5047255 0.91 RARA (0.42) RARARARBRARGMAOAMAOB
SCHEMBL5050811 0.84 RARA (0.43) RARARARBRARGRXRARXRB
SCHEMBL5050808 0.84 RARA (0.43) RARARARBRARGRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARA 1/4885RARB 2/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.